GlaxoSmithKline plc announced positive results from the B-Well 1 and B-Well 2 pivotal Phase III clinical trials evaluating bepirovirsen (GSK3228836), an investigational antisense oligonucleotide (ASO) designed as the first-in-class finite-duration therapy capable of achieving functional cure in patients with chronic hepatitis B (CHB). The trials met their primary efficacy endpoints, with bepirovirsen demonstrating statistically significant and clinically meaningful functional cure rates when combined with standard-of-care nucleos(t)ide analogue therapy.

The positive trial outcomes represent a watershed moment for millions of hepatitis B patients globally and underscore a fundamental paradigm shift in therapeutic goal-setting: from indefinite viral suppression to durable viral eradication and immune reconstitution.

Understand the Chronic Hepatitis B market trends: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market

Chronic Hepatitis B: A Global Health Crisis with High Unmet Needs

Chronic hepatitis B ranks among the world’s most formidable infectious disease challenges. More than 250 million people worldwide carry the hepatitis B virus chronically—a burden that claims approximately 1.1 million lives annually and accounts for roughly 56% of all primary liver cancer cases globally. Yet despite the magnitude of this public health burden, treatment advances have stagnated for decades within a paradigm of indefinite viral suppression.​

Current standard-of-care nucleos(t)ide analogues—entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide—represent remarkable achievements in antiviral chemistry, providing potent suppression of HBV DNA replication and halting disease progression in many patients. However, these therapies exhibit a critical limitation: they provide only viral suppression, not viral clearance. Patients receiving nucleos(t)ide analogues typically require lifelong treatment, as viral rebound occurs in the majority of individuals who discontinue therapy. Beyond this therapeutic constraint, functional cure rates—defined as sustained loss of hepatitis B surface antigen (HBsAg) and undetectable HBV DNA for at least 24 weeks following treatment discontinuation—remain exceptionally low with nucleos(t)ide analogue monotherapy, typically around 1%.​

This limitation creates a profound unmet need, particularly for younger patients who might otherwise face 50+ years of daily antiviral therapy, with attendant adherence challenges, potential long-term toxicities, and diminished quality of life.

Bepirovirsen Clinical Trial Results: Demonstrating Functional Cure for the First Time

GSK conducted two large, randomized, double-blind, placebo-controlled Phase III trials (B-Well 1 [NCT05630807] and B-Well 2 [NCT05630820]) enrolling over 1,800 patients across 29 countries. These trials enrolled nucleos(t)ide analogue-treated participants with chronic hepatitis B and baseline hepatitis B surface antigen (HBsAg) levels ≤3,000 IU/mL—a population representing the majority of treated CHB patients in clinical practice.

Primary Endpoint Achievement: Both B-Well trials met their primary efficacy endpoint. Bepirovirsen demonstrated statistically significant functional cure rates when administered as a 24-week course in combination with standard nucleos(t)ide analogue therapy. Functional cure was defined as sustained HBsAg loss and undetectable HBV DNA (maintained for ≥24 weeks) after the finite course of treatment concluded.​

Remarkable Efficacy in Lower Baseline HBsAg Cohorts: A key ranked secondary endpoint evaluated functional cure rates in the biomarker-selected subgroup of patients with baseline HBsAg ≤1,000 IU/mL. In this population, bepirovirsen demonstrated even greater functional cure rates—a finding with substantial clinical significance. This biomarker-driven enrichment strategy aligns with evolving treatment paradigms advocating for quantitative HBsAg-driven patient stratification and personalized therapy selection.​

Comparative Efficacy: Functional cure rates achieved with bepirovirsen plus standard of care substantially exceeded those achieved with standard of care alone—a differential that was statistically significant across all ranked efficacy endpoints.

The data represent the first demonstration of clinically meaningful functional cure rates in a large Phase III population—a result that fundamentally reshapes expectations for hepatitis B therapy and validates two decades of antisense oligonucleotide development targeting the hepatitis B genome.

Bepirovirsen Mechanism of Action: Triple-Mode Viral Inhibition

Bepirovirsen operates through an elegantly rational biochemical strategy targeting all hepatitis B virus RNA transcripts. The 20-mer modified antisense oligonucleotide comprises three distinct antiviral mechanisms working in concert:

RNA Targeting and Viral Suppression: Bepirovirsen binds with high specificity and affinity to complementary HBV RNA sequences, including both messenger RNA and pregenomic RNA—the genetic blueprints for viral protein synthesis and DNA replication. Once bound, the oligonucleotide recruits the cell’s ribonuclease H enzyme, which digests the targeted RNA strand, rendering it unavailable for protein translation and viral DNA synthesis. Preclinical studies demonstrated dose-dependent reductions exceeding 90% in hepatic HBV RNA and 99% in hepatic HBV DNA in transgenic mouse models treated with optimal dosing regimens.​

Hepatitis B Surface Antigen Suppression: By eliminating the RNA template for viral protein synthesis, bepirovirsen profoundly suppresses circulating levels of hepatitis B surface antigen (HBsAg)—the immunologically critical viral protein that signals ongoing infection and maintains the immunological tolerance to HBV that characterizes chronic infection. Preclinical data showed approximately 99% suppression of serum HBsAg levels in HBV transgenic models.​

Immune System Activation: Bepirovirsen possesses a unique immunostimulatory property not present in purely inhibitory antiviral therapies. The oligonucleotide stimulates innate immune responses through engagement of Toll-like receptor 8 (TLR8)—a pattern recognition receptor expressed on antigen-presenting cells and immune effector cells. This immunostimulatory activity theoretically enhances the likelihood that the immune system can mount and sustain effective adaptive immune responses against residual or emerging HBV, increasing the durability of functional cure even after treatment cessation.​

This triple-action mechanistic framework—combining direct viral suppression, antigen reduction, and immune activation—represents a rationally designed approach to break the immunological tolerance that perpetuates chronic HBV infection.

 Bepirovirsen Safety and Tolerability Profile

Across the B-Well trials, bepirovirsen demonstrated an acceptable safety and tolerability profile consistent with results from earlier-stage studies. The most commonly observed adverse events were mild-to-moderate in severity and included transient increases in alanine aminotransferase (ALT) levels—a finding anticipated given the mechanism of action (viral clearance can trigger transient hepatocellular inflammation). No unexpected safety signals emerged, and the safety profile was comparable between treatment and control groups.​

The tolerability findings are particularly noteworthy given that bepirovirsen requires only 24 weeks of treatment (twice-weekly subcutaneous injection) compared to the indefinite oral dosing required by nucleos(t)ide analogues. This finite treatment duration and injection-based administration may offer practical advantages for patient adherence and quality-of-life considerations, particularly in younger patients with decades of productive life remaining.

FDA Regulatory Pathway and Development Timeline

Bepirovirsen has received multiple designations from global health authorities underscoring its innovation status and the unmet clinical need it addresses:

• FDA Fast Track Designation (United States)
• Breakthrough Therapy Designation (China)
• SENKU Designation (Japan)​

These expedited review pathways reflect regulatory recognition that bepirovirsen represents a meaningful advancement beyond current treatment standards.

GSK plans to submit complete Phase III data for presentation at upcoming scientific congresses and publication in peer-reviewed journals. Global regulatory filings are planned to commence in the first quarter of 2026, with submissions anticipated to the FDA, EMA, and other major regulatory authorities. If approved as envisioned, bepirovirsen would become the first finite-duration, six-month therapeutic option for chronic hepatitis B—fundamentally altering the treatment landscape for a disease affecting a quarter-billion individuals globally.

Strategic Significance: ASO Oligonucleotide Platform and Sequential Therapy Development

Bepirovirsen’s success validates the therapeutic potential of antisense oligonucleotide technology for targeting persistent viral infections—a platform that GSK has strategically invested in through licensing arrangements and collaborative partnerships. In October 2023, GSK acquired exclusive licensing rights to JNJ-3989 (a hepatitis B capsid assembly inhibitor) specifically to enable sequential combination therapy with bepirovirsen in Phase II trials commencing in 2024. The rationale for this sequential approach is compelling: whereas bepirovirsen targets viral RNA and antigen suppression, capsid inhibitors operate through distinct mechanisms, potentially allowing even higher functional cure rates through complementary mechanisms of action.​

This strategy positions GSK to potentially advance the field beyond monotherapy to combination or sequential regimens capable of curing hepatitis B in broader patient populations—including those with higher baseline HBsAg levels who did not achieve functional cure with monotherapy.

Clinical Practice Context and Treatment Evolution

The B-Well trial data arrive at a critical inflection point in hepatitis B therapy. Major treatment guidelines—including the 2025 European Association for the Study of the Liver (EASL) Clinical Practice Guidelines and the 2025 Canadian Association for the Study of the Liver guidelines—increasingly emphasize functional cure as the optimal treatment goal, moving beyond the previous paradigm of indefinite viral suppression toward finite, curative therapies. These updated guidelines explicitly recommend quantitative HBsAg measurements to guide treatment decisions and patient stratification—precisely the biomarker-driven approach validated by the B-Well trials’ superior efficacy in the HBsAg ≤1,000 IU/mL population.​

The World Health Organization has established an ambitious target of eliminating hepatitis B as a public health threat by 2030—a goal that requires not only expanded vaccination and prevention but also curative therapeutic options for the existing population of 250+ million chronically infected individuals. Bepirovirsen represents a critical tool toward that aspirational endpoint.​

Global Public Health Impact

The implications of bepirovirsen’s efficacy extend far beyond individual patient benefit. If approved and deployed globally, the availability of a finite, curative therapy for hepatitis B could catalyze several downstream clinical and public health benefits:

Reduced Cirrhosis and Hepatocellular Carcinoma: Functional cure is associated with sustained reduction in the risk of long-term liver complications, including cirrhosis progression and hepatocellular carcinoma development—the ultimate drivers of hepatitis B mortality. Patients achieving functional cure can discontinue antiviral therapy without risk of hepatic decompensation, fundamentally altering the natural history trajectory of the disease.

Improved Quality of Life and Medication Burden: The transition from indefinite daily oral therapy to a 24-week subcutaneous injection regimen addresses a critical quality-of-life consideration for younger patients with normal life expectancies. The psychological and practical burden of daily medication—with associated adherence challenges, potential long-term organ toxicities, and identity as a “chronically medicated” patient—would be eliminated through functional cure.

Epidemiological Impact: Successful treatment of large cohorts of chronically infected patients, particularly in high-prevalence regions of Asia and Africa, could substantially reduce the reservoir of chronically infected individuals and the transmission risk to unvaccinated contacts, supporting WHO elimination goals.

Chronic Hepatitis B Competitive Landscape and Developmental Momentum

Bepirovirsen is advancing within an increasingly dynamic hepatitis B drug development landscape. Multiple competing approaches—including other antisense oligonucleotides, hepatitis B capsid assembly inhibitors, therapeutic vaccines, entry inhibitors, and nucleic acid polymers—are in clinical development across the global biopharma industry. However, bepirovirsen appears to be the furthest advanced in demonstrating clinically meaningful functional cure rates in large randomized Phase III trials, positioning it as a potential first-mover advantage in the finite-cure therapeutic space.

This competitive positioning is particularly significant given the enormous market opportunity: the current nucleos(t)ide analogue market for hepatitis B exceeds $5 billion annually, with potential for substantial expansion if curative options become available.

Path Forward and Clinical Development Vision

GSK’s stated vision is to establish bepirovirsen not only as a monotherapy option but as a foundational “backbone” for future sequential treatment regimens. The planned Phase II trials combining bepirovirsen with JNJ-3989 represent the first step toward this vision, potentially enabling higher functional cure rates in patients who do not achieve sustained viral clearance with bepirovirsen monotherapy. This sequential approach aligns with conceptual models of hepatitis B cure that recognize the complexity of breaking immunological tolerance and ensuring durable immune control.

Looking forward, the convergence of improved antiviral technologies, refined patient stratification using quantitative biomarkers, and treatment guidelines emphasizing functional cure as the primary goal suggests that hepatitis B—long considered a condition requiring lifelong therapy—may soon transition into the category of treatable, curable diseases.